TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10100557

Group type: EXPERIMENTAL
Intervention: CsA + MTX
Number of subjects: 30

Group type: COMPARATOR
Intervention: CsA alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (CsA + MTX and CsA alone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with acute leukemia
Number of subjects: 30
Study: 8901155

Group type: EXPERIMENTAL
Intervention: Test patch (Dermestril)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference patch
Number of subjects: 28
Study: 1746424

Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/day
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Inactive drug therapy (control)
Number of subjects: 4000
Study: 7048879

Group type: EXPERIMENTAL
Intervention: Pindolol (mean dose 28 +/- 5 mg twice a day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methyldopa (673 +/- 158 mg three times a day)
Number of subjects: 30
Study: 30653147

Group type: EXPERIMENTAL
Intervention: Pre-administration of remifentanil before propofol infusion (Group R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Co-administration of remifentanil with propofol (Group N)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre-administration of remifentanil (Group R)
Number of subjects: 60
Study: 29891003

Group type: EXPERIMENTAL
Intervention: Real acupuncture on the acu-point Bi'nao
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture on the sham Bi'nao
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture therapy
Number of subjects: 0
Study: 26706403

Group type: EXPERIMENTAL
Intervention: One-time unconditional income transfers to all households (T1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-time unconditional income transfers to the poorest 20% of households (T2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (other villages)
Number of subjects: 0
Study: 24659430

Group type: EXPERIMENTAL
Intervention: Intranasal OXT (24 IU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study: 22669143

Group type: EXPERIMENTAL
Intervention: Catuama (herbal compound), 2 capsules each day for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 72
Study: 21130328

Group type: EXPERIMENTAL
Intervention: Stainless steel orthodontic wires exposed in vivo for varying durations
Number of subjects: 30

Group type: COMPARATOR
Intervention: As-received control samples of stainless steel orthodontic wires
Number of subjects: 30
Study: 17414236

Group type: EXPERIMENTAL
Intervention: Bupropion (n = 18)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 39
Study: 10642289

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo CPAP (administered at ineffective pressure)
Number of subjects: 39
Study: 9071515

Group type: EXPERIMENTAL
Intervention: Levonorgestrel rod (LNG ROD) implants
Number of subjects: 1198

Group type: COMPARATOR
Intervention: NORPLANT implants
Number of subjects: 1198
Study: 8446137

Group type: EXPERIMENTAL
Intervention: Captopril (25 to 50 mg twice daily, with or without hydrochlorothiazide)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg per day, with or without hydrochlorothiazide)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 379
Study: 3941567

Group type: EXPERIMENTAL
Intervention: Internal mammary artery grafts
Number of subjects: 98

Group type: COMPARATOR
Intervention: Saphenous vein grafts with placebo
Number of subjects: 98

Group type: COMPARATOR
Intervention: Saphenous vein grafts with aspirin and dipyridamole
Number of subjects: 98

Group type: COMPARATOR
Intervention: Saphenous vein grafts
Number of subjects: 98
Study: 29488276

Group type: EXPERIMENTAL
Intervention: Exenatide, 5 μg BID for 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide, 3 mg daily for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: GG genotype (control group)
Number of subjects: 0
Study: 27198235

Group type: EXPERIMENTAL
Intervention: Contingent incentives (CS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-contingent incentives (NS)
Number of subjects: 41
Study: 25141246

Group type: EXPERIMENTAL
Intervention: Ibuprofen/famotidine fixed-dose tablet
Number of subjects: 776

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 776
Study: 23394465

Group type: EXPERIMENTAL
Intervention: Web application
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Video conferencing (Skype)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard home health care (Control)
Number of subjects: 34
Study: 20501682

Group type: EXPERIMENTAL
Intervention: T4 replacement therapy
Number of subjects: 94
Study: 17594774

Group type: EXPERIMENTAL
Intervention: Case vignette describing a man with current symptoms of mania
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Case vignette describing a man with current symptoms of depression
Number of subjects: 387

Group type: COMPARATOR
Intervention: General public attitudes
Number of subjects: 387
Study: 16669971

Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 60

Group type: COMPARATOR
Intervention: fosinopril
Number of subjects: 60
Study: 12785122

Group type: EXPERIMENTAL
Intervention: Fixed combination of 500 mg acetylsalicylic acid (ASA) and 30 mg pseudoephedrine (PSE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Equally single dosed drugs (ASA and PSE)
Number of subjects: 12
Study: 10744291

Group type: EXPERIMENTAL
Intervention: Continuous suturing
Number of subjects: 101

Group type: COMPARATOR
Intervention: Interrupted suturing
Number of subjects: 101
Study: 8862260

Group type: EXPERIMENTAL
Intervention: rhuIFN-gamma with thalidomide and conventional multidrug chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhuIFN-gamma only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhuIFN-gamma without concomitant chemotherapy
Number of subjects: 0
Study: 1299501

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, 7% carbohydrate)
Number of subjects: 10
Study: 29458323

Group type: EXPERIMENTAL
Intervention: Polyurethane adhesive keyhole dressing together with a polyurethane semipermeable transparent dressing
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (polyurethane adhesive keyhole dressing)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sedated patients
Number of subjects: 300
Study: 27106721

Group type: EXPERIMENTAL
Intervention: DHA+EPA treatment (4 g/day for 15-18 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25518878

Group type: EXPERIMENTAL
Intervention: Proactive motivational telephone outreach with eight weeks of nicotine replacement therapy and eight sessions of specialized telephone counseling over two months, followed by monthly maintenance counseling for four months.
Number of subjects: 3840

Group type: COMPARATOR
Intervention: VHA usual care (control group).
Number of subjects: 3840
Study: 22456094

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20153158

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (4 microg, inhaled 6-9 times daily, with a night pause; dose reduced to 2 microg if side effects occurred)
Number of subjects: 63
Study: 18418961

Group type: EXPERIMENTAL
Intervention: Removing dampness and purgative (RDP) method plus routine Western medicine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine Western medicine
Number of subjects: 120
Study: 16827811

Group type: EXPERIMENTAL
Intervention: Nadolol plus 5-ISMN
Number of subjects: 109

Group type: COMPARATOR
Intervention: Endoscopic band ligation
Number of subjects: 109
Study: 12806495

Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional Ward (GW)
Number of subjects: 74
Study: 10812982

Group type: EXPERIMENTAL
Intervention: Ketanov
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analgin
Number of subjects: 50
Study: 8841801

Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor (UTI), vaginal suppository (5000 U) daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritodrine, high doses up to 300 micrograms/min initially, then maintenance dose until 35 weeks of gestation
Number of subjects: 0
Study: 1310715

Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg once daily for 3 days
Number of subjects: 404

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily for 7 days
Number of subjects: 404
Study: 6596055

Group type: EXPERIMENTAL
Intervention: High P/S ratio diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low P/S ratio diet (Control)
Number of subjects: 0
Study: 30576841

Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training (VR-JIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPS services-as-usual + VR-JIT
Number of subjects: 0

Group type: COMPARATOR
Intervention: IPS services-as-usual
Number of subjects: 0
Study: 30070579

Group type: EXPERIMENTAL
Intervention: Indirect measures of implicit attitudes
Number of subjects: 24015

Group type: EXPERIMENTAL
Intervention: Dual-attitude model
Number of subjects: 24015

Group type: EXPERIMENTAL
Intervention: Validation of indirect measures
Number of subjects: 24015
Study: 27052635

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) for 52 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Metformin (MET) for 52 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Metformin (MET) for 24 weeks (open-label phase)
Number of subjects: 87
Study: 25116690

Group type: EXPERIMENTAL
Intervention: Psychotherapy (Narrative Exposure Therapy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PTSD individuals
Number of subjects: 34

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 34
Study: 22239483

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC) intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 120
Study: 20016870

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus amoxicillin‐clavulanate (Group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cefepime (Group B)
Number of subjects: 58
Study: 18585831

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (PV) + Influenza vaccine (IV)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Influenza vaccine (IV)
Number of subjects: 167
Study: 15606590

Group type: EXPERIMENTAL
Intervention: Vamin 18 infusion (500 mls) administered immediately after induction of anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no Vamin 18 administered)
Number of subjects: 20
Study: 12113994

Group type: EXPERIMENTAL
Intervention: NIDCAP care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control care
Number of subjects: 20
Study: 10434232

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate vaginal ovule
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clindamycin phosphate vaginal cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clindamycin phosphate sterile solution (IV infusion)
Number of subjects: 12
Study: 7811160

Group type: EXPERIMENTAL
Intervention: Benztropine mesylate
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Neuroleptic medication dose reduction
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 149
Study: 2349364

Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5 mg) three times daily for 4 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxazepam (10 mg) three times daily for 4 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of tianeptine and oxazepam
Number of subjects: 12
Study: 37094

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31100713

Group type: COMPARATOR
Intervention: SBIRT
Number of subjects: 439

Group type: COMPARATOR
Intervention: e‐SBIRT
Number of subjects: 439
Study: 28244706

Group type: EXPERIMENTAL
Intervention: Home-based dietary and physical activity intervention (Her Shape Program)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 25870324

Group type: EXPERIMENTAL
Intervention: Typbar-TCV (single dose)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Typbar (Vi polysaccharide, single dose)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Typbar-TCV (single dose) in OLT
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Typbar-TCV (2 years post-vaccination)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Typbar-TCV (OLT)
Number of subjects: 981
Study: 24059784

Group type: EXPERIMENTAL
Intervention: Integrated treatment for Substance abuse and Partner violence (I-StoP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cognitive behavioral treatment addressing substance use disorders (CBT-SUD+)
Number of subjects: 52
Study: 21865352

Group type: EXPERIMENTAL
Intervention: Continuous testosterone (TE, n = 8; 100 mg testosterone enanthate, im injection)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Monthly cycled testosterone (MO, n = 8; alternating months of testosterone and placebo)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL, n = 8)
Number of subjects: 24
Study: 19273709

Group type: EXPERIMENTAL
Intervention: Weekly bolus irinotecan, FU, and leucovorin (IFL)
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Weekly bolus fluorouracil and leucovorin (FU/LV)
Number of subjects: 1264
Study: 17390741

Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Reduced-exposure cyclosporine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 15054036

Group type: EXPERIMENTAL
Intervention: rHuEPO + rHuG-CSF (arm A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive care (arm B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rHuEPO alone after 12 weeks for responders in arm A
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cost per patient
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quality of life assessment with FACT-An scale
Number of subjects: 60
Study: 11964529

Group type: EXPERIMENTAL
Intervention: Phenotyping
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Genotyping
Number of subjects: 541

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 541
Study: 9563888

Group type: EXPERIMENTAL
Intervention: Capecitabine administered after food
Number of subjects: 11

Group type: COMPARATOR
Intervention: Capecitabine administered after fasting
Number of subjects: 11
Study: 7637045

Group type: EXPERIMENTAL
Intervention: 3-drug solution (papaverine + phentolamine + prostaglandin E1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2-drug solution (papaverine + phentolamine)
Number of subjects: 20
Study: 2515399

Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 20
Study: 687502

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30726465

Group type: EXPERIMENTAL
Intervention: Use of SPF 30 on the face, neck and chest (n=64)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: No sunscreens (n=10)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Confined from sun exposure for 24h (n=21)
Number of subjects: 95
Study: 28319871

Group type: EXPERIMENTAL
Intervention: IgG and IgM MDA-LDL
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: IgG and IgM apoB-IC
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Autoantibody titers to MDA-LDL and apoB-IC
Number of subjects: 220
Study: 26614140

Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Washing cuff before insertion
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Washing mouth before removing laryngeal mask airway
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no supplementary method)
Number of subjects: 240
Study: 23223597

Group type: EXPERIMENTAL
Intervention: 400 mg tribendimidine once
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 400 mg tribendimidine daily for 3 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: 75 mg/kg praziquantel in 1 day divided in 3 doses
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Single-dose tribendimidine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 74
Study: 21791091

Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 UaXa o.d.
Number of subjects: 274

Group type: COMPARATOR
Intervention: UFH 5,000 IU t.i.d.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 274

Group type: COMPARATOR
Intervention: Patients without cancer
Number of subjects: 274
Study: 19335078

Group type: EXPERIMENTAL
Intervention: Magnesium-enriched hydroxyapatite (mHA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Autologous bone (AB)
Number of subjects: 15
Study: 16934269

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 56
Study: 15306157

Group type: EXPERIMENTAL
Intervention: Serum clotted on room temperature (serum‐RT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Serum clotted on ice (serum‐I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Platelet poor plasma (PPP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma sCD40L in patients with thrombosis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plasma sCD40L in patients without thrombosis
Number of subjects: 30
Study: 11009268

Group type: EXPERIMENTAL
Intervention: Pravastatin plus anti-hypertensive drugs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypertensive agents and diet control alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antihypertensive agents (normolipidemia)
Number of subjects: 60
Study: 8827744

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 428

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 428
Study: 1747505

Group type: EXPERIMENTAL
Intervention: Famotidine 40mg h.s.
Number of subjects: 280

Group type: COMPARATOR
Intervention: Ranitidine 300mg h.s.
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Famotidine 40mg h.s. and Ranitidine 300mg h.s.
Number of subjects: 280
Study: 6175138

Group type: EXPERIMENTAL
Intervention: Pimozide treatment
Number of subjects: 11
Study: 29506034

Group type: EXPERIMENTAL
Intervention: VYC‐15L (Juvéderm Volbella XC)
Number of subjects: 124
Study: 27824330

Group type: EXPERIMENTAL
Intervention: PEI-pPDGF-B polyplexes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Collagen alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhPDGF-BB
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEI vector
Number of subjects: 0
Study: 24433244

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study: 24571703

Group type: EXPERIMENTAL
Intervention: Stannous-containing sodium fluoride dentifrice (Oral-B(®) Pro-Expert Sensitive)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sodium fluoride/potassium nitrate dentifrice (Sensodyne(®) Pronamel(®))
Number of subjects: 35
Study: 22578899

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 20221984

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with ILM peeling (group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide (TA) injection (group B)
Number of subjects: 41
Study: 17564719

Group type: COMPARATOR
Intervention: PDT‐IVTA with standard light fluence of 50 J/cm(2) (SPDT‐IVTA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PDT‐IVTA with reduced light fluence of 25 J/cm(2) (RPDT‐IVTA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups (SPDT‐IVTA, RPDT‐IVTA, IVB)
Number of subjects: 30
Study: 15637533

Group type: EXPERIMENTAL
Intervention: CCI-779 (25, 75, or 250 mg once weekly)
Number of subjects: 50
Study: 11802924

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg once daily
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg twice daily
Number of subjects: 1529

Group type: COMPARATOR
Intervention: Aciclovir
Number of subjects: 1529
Study: 10233315

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) levels > 2 microgram/g of dust
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) levels between 0.1 and 2 microgram/g of dust
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) levels < 0.1 microgram/g of dust
Number of subjects: 41
Study: 7813329

Group type: EXPERIMENTAL
Intervention: Contemporary pulmonary embolism thrombolysis
Number of subjects: 0
Study: 2551242

Group type: EXPERIMENTAL
Intervention: Powder form of ADM, MMC, and CDDP suspended in lipiodol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: URO form of ADM and MMC dissolved with Urografin mixed with lipiodol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological saline water form of ADM and MMC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDDP solution as usually used
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Powder form of CDDP
Number of subjects: 0
Study: 1217693

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nalorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30794314

Group type: EXPERIMENTAL
Intervention: Peanut patch containing 250 μg of peanut protein (n=238)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo (n=118)
Number of subjects: 356